Blastic phase chronic myelogenous leukemia

Blastic Phase Chronic Myelogenous Leukemia (BP-CML), also known as blast crisis phase of chronic myelogenous leukemia (CML), is a critical phase in the progression of CML, characterized by the rapid increase of blast cells in the blood and bone marrow. This phase represents a transition from a relatively stable condition to a highly aggressive and life-threatening form of leukemia.

Overview

Chronic myelogenous leukemia is a type of cancer that affects the bone marrow and produces large numbers of immature white blood cells. CML progresses through three phases: the chronic phase, the accelerated phase, and the blastic phase. The blastic phase occurs when the disease transforms into an acute leukemia, with more than 20% of cells in the blood or bone marrow being blasts (immature white blood cells).

Pathophysiology

The progression to blastic phase is typically marked by additional genetic changes beyond the Philadelphia chromosome, which is a hallmark of CML. These changes can lead to increased proliferation and reduced apoptosis (programmed cell death) of the leukemic cells. The blastic phase can manifest as either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), depending on the type of blasts that predominate.

Symptoms

Symptoms of BP-CML are more severe than those of earlier phases and may include:

• Fatigue
• Fever
• Night sweats
• Weight loss
• Increased susceptibility to infections
• Bone pain
• Anemia
• Easy bleeding and bruising

Diagnosis

Diagnosis of BP-CML involves a combination of clinical evaluation, blood tests, and bone marrow examination. Key diagnostic tests include:

• Complete blood count (CBC)
• Bone marrow biopsy
• Cytogenetic analysis
• Molecular testing for BCR-ABL1 gene rearrangement

Treatment

Treatment of BP-CML is challenging and aims to return the patient to the chronic phase of the disease or to achieve a complete remission. Treatment options include:

• Tyrosine kinase inhibitors (TKIs) - although their effectiveness is often limited in the blastic phase
• Chemotherapy
• Stem cell transplantation, which is considered the only potentially curative option

Prognosis

The prognosis for patients in the blastic phase of CML is generally poor, with median survival times ranging from a few months to a year without effective treatment. Early detection and treatment of CML in the chronic phase can help prevent progression to the blastic phase.

See Also

• Leukemia
• Bone marrow transplant
• Hematology